An evaluation of the drug-drug interaction between proton-pump inhibitors and EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients.

被引：0
|
作者：
Chan, Alexandre
Chen, Bingrong
Ng, Raymond [2 ]
Yong, Wei-Peng [1 ]
Ko, Yu
机构：
[1] Natl Univ Singapore, Inst Canc, Singapore 117548, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：E221 / E222
页数：2
相关论文
共 50 条
  • [21] Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions
    Peters, Solange
    Zimmermann, Stefan
    Adjei, Alex A.
    CANCER TREATMENT REVIEWS, 2014, 40 (08) : 917 - 926
  • [22] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [23] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [24] Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction
    Ozdemir, N.
    Toptas, S.
    Sendur, M. A. N.
    Yazici, O.
    Oksuzoglu, B.
    Silay, K.
    Zengin, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
    Hunter, S.
    Nickless, G.
    Ghosh, S.
    Lal, R.
    Merrick, S. A.
    Montes, A.
    Smith, D.
    Spicer, J.
    Karapanagiotou, E.
    LUNG CANCER, 2017, 103 : S34 - S35
  • [26] EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
  • [27] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [28] AN ANALYSIS OF THE DRUG-DRUG INTERACTION BETWEEN DOCETAXEL AND GEFITINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Motonaga, Masanori
    Makino, Yoshinori
    Yamamoto, Noboru
    Makihara, Reiko A.
    Tamura, Tomohide
    Hayashi, Yoshikazu
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S575 - S576
  • [29] Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
    Das, Millie
    Padda, Sukhmani K.
    Frymoyer, Adam
    Zhou, Lisa
    Riess, Jonathan W.
    Neal, Joel W.
    Wakelee, Heather A.
    LUNG CANCER, 2015, 89 (03) : 280 - 286
  • [30] Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
    Chen, K.
    Yu, X.
    Wang, H.
    Huang, Z.
    Xu, Y.
    Gong, L.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1736 - S1737
12345